Sitemap > Breaking Research > Cardiovascular Disorders
Displaying 251 - 300 of 4862 results
- Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability.
- Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice.
- Angiotensin receptor blockade with candesartan attenuates atherosclerosis, plaque disruption, and macrophage accumulation within the plaque in a rabbit model.
- Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis.
- Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
- SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa.
- 5-Amidinoindoles as dual inhibitors of coagulation factors IXa and Xa.
- The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.
- A protein tyrosine phosphatase inhibitor accelerates angiogenesis in a rat model of hindlimb ischemia.
- p38 alpha mitogen-activated protein kinase inhibition improves cardiac function and reduces myocardial damage in isoproterenol-induced acute myocardial injury in rats.
- In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor.
- FR167653 diminishes infarct size in a murine model of myocardial ischemia-reperfusion injury.
- Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial.
- Mitochondrial KATP channels in hindlimb remote ischemic preconditioning of skeletal muscle against infarction.
- Effect of 3beta-hydroxysteroid dehydrogenase inhibition by trilostane on blood pressure in the Dahl salt-sensitive rat.
- Inhibition of endogenous leptin protects mice from arterial and venous thrombosis.
- Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review.
- Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis.
- Cardiovascular risk factors and cognitive function in adults 30-59 years of age (NHANES III).
- Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV.
- A novel approach to treatment of hypertension in diabetic patients - a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 - rationale and design [ISRCTN55725285].
- The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care.
- High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial.
- Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
- Effects of a new phosphodiesterase enzyme type V inhibitor (UK 343-664) versus milrinone in a porcine model of acute pulmonary hypertension.
- Safety of rosuvastatin.
- Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study).
- Nucleotide analogues containing 2-oxa-bicyclo[2.2.1]heptane and l-alpha-threofuranosyl ring systems: interactions with P2Y receptors.
- Meta-analysis of allograft bypass grafting to infrapopliteal arteries.
- Long-term outcome following thrombembolectomy in the upper extremity.
- Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials.
- NOS3 deficiency augments hypoxic pulmonary vasoconstriction and enhances systemic oxygenation during one-lung ventilation in mice.
- p38 MAP kinase inhibitor reverses stress-induced cardiac myocyte dysfunction.
- BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
- A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats.
- Regulated angiogenesis and vascular regression in mice overexpressing vascular endothelial growth factor in airways.
- The association between blood pressure, hypertension, and cerebral white matter lesions: cardiovascular determinants of dementia study.
- Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-gamma ligand pioglitazone.
- Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury.
- Estrogen plus progestin and risk of venous thrombosis.
- Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis.
- [Pharmacological profiles and clinical effects of olmesartan medoxomil, a novel angiotensin II receptor blocker]
- Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis.
- [Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results]
- Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure.
- VEGF receptor antagonism blocks arteriogenesis, but only partially inhibits angiogenesis, in skeletal muscle of exercise-trained rats.
- Novel therapeutic approach for cancer using four cardiovascular hormones.
- The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease.
- Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity.
- Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 Next >